Date: 2025/05/19 - 22:32
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk factors. Tirzepatide's dual effects on GLP-1 and GIP may explain its superior performance.
Date: 2025/05/18 - 16:31
Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular events after just six months of starting the medication, a new study indicates.